Literature DB >> 7351580

Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents.

J Wilimas, J R Goff, H R Anderson, J W Langston, E Thompson.   

Abstract

Since 1974 we have entered 12 children with sickle cell disease and strokes on a transfusion protocol to maintain hemoglobin S less than 20%. Serial arteriography, EEGs, brain or CT scans, and neuropsychologic testing were also obtained. Transfusion has been stopped in ten patients after one to two years. Seven of these ten patients have had second strokes five weeks to 11 months after cessation of transfusion (median three months). Arteriography was normal at the time of the initial stroke in two patients; one of these had a second stroke. Arteriograms did not improve during transfusion therapy. EEGs and brain and CT scans were occasionally useful at the time of the initial stroke but were of little value in following these patients. Neuropsychologic testing indicated severe impairment of sensory-motor and cognitive processes at the time of the initial stroke and was useful in following improvement or deterioration and in designing remedial education programs. We conclude that short-term transfusion therapy will not prevent second strokes once transfusion is stopped and that arteriography is of limited value in these patients.

Entities:  

Mesh:

Year:  1980        PMID: 7351580     DOI: 10.1016/s0022-3476(80)80803-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

2.  Cerebral blood flow mapping using stable xenon-enhanced CT in sickle cell cerebrovascular disease.

Authors:  Y Numaguchi; J S Haller; J R Humbert; A E Robinson; W W Lindstrom; L M Gruenauer; J E Carey
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

3.  White matter damage in asymptomatic patients with sickle cell anemia: screening with diffusion tensor imaging.

Authors:  B Sun; R C Brown; L Hayes; T G Burns; J Huamani; D J Bearden; R A Jones
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-17       Impact factor: 3.825

4.  Differences in Activation and Deactivation in Children with Sickle Cell Disease Compared with Demographically Matched Controls.

Authors:  B Sun; R C Brown; T G Burns; D Murdaugh; S Palasis; R A Jones
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

5.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Authors:  Russell E Ware; Ronald W Helms
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

6.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Higher executive abilities following a blood transfusion in children and young adults with sickle cell disease.

Authors:  Anna M Hood; Allison A King; Melanie E Fields; Andria L Ford; Kristin P Guilliams; Monica L Hulbert; Jin-Moo Lee; Desiree A White
Journal:  Pediatr Blood Cancer       Date:  2019-07-03       Impact factor: 3.167

Review 8.  Stroke in children with sickle cell anaemia: aetiology and treatment.

Authors:  C H Pegelow
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

9.  How I treat and manage strokes in sickle cell disease.

Authors:  Adetola A Kassim; Najibah A Galadanci; Sumit Pruthi; Michael R DeBaun
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

10.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.